Dual specificity protein phosphatases: Therapeutic targets for cancer and Alzheimer's disease

Annual Review of Pharmacology and Toxicology

Volumn 45, Issue , 2005, Pages 725-750

  Ducraet, Alexander P ^a   Vogt, Andreas ^a   Wipf, Peter ^a   Lazo, John S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cdc25; Cdk; Drug discovery; MAPK; MKP

Indexed keywords

COSCINOSULFATE; DNACIN B1; DYSIDIOLIDE; ENZYME INHIBITOR; GEFITINIB; HETEROCYCLIC COMPOUND; IMATINIB; MENADIONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; NATURAL PRODUCT; PHENOL DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; QUINONE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CANCER; CELL CYCLE; DEPHOSPHORYLATION; DRUG TARGETING; ENZYME INACTIVATION; ENZYME INHIBITOR COMPLEX; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HELA CELL; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASE; PROTEASE INHIBITORS;

EID: 13844312725     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.45.120403.100040     Document Type: Review

References (152)

1. Hunter T. 1995. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell 80:225-36
2. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. 2001. The sequence of the human genome. Science 291:1304-51
3. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, et al. 2004. Protein tyrosine phosphatases in the human genome. Cell 117:699-711
4. Denu JM, Stuckey JA, Saper MA, Dixon JE. 1996. Form and function in protein dephosphorylation. Cell 87:361-64
5. Zhang ZY. 2002. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 42:209-34
6. Yuvaniyama J, Denu JM, Dixon JE, Saper MA. 1996. Crystal structure of the dual specificity protein phosphatase VHR. Science 272:1328-31
7. Hanks SK. 2003. Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol. 4:111.1-7
8. Millar JB, Russell P. 1992. The cdc25 M-phase inducer: an unconventional protein phosphatase. Cell 68:407-10
9. Honda R, Ohba Y, Yasuda H. 1992. The cell cycle regulator, human p50weel, is a tyrosine kinase and not a serine/tyrosine kinase. Biochem. Biophys. Res. Commun. 186:1333-38
10. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. 1997. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell Biol. 17:571-83
11. Senderowicz AM, Sausville EA. 2000. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. 92:376-87
12. Sadhu K, Reed SI, Richardson H, Russell P. 1990. Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl. Acad. Sci. USA 87:5139-43
13. Strausfeld U, Fernandez A, Capony JP, Girard F, Lautredou N, et al. 1994. Activation of p34cdc2 protein kinase by microinjection of human cdc25C into mammalian cells. Requirement for prior phosphorylation of cdc25C by p34cdc2 on sites phosphorylated at mitosis. J. Biol. Chem. 269:5989-6000
14. Millar JB, Blevitt J, Gerace L, Sadhu K, Featherstone C, Russell P. 1991. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells. Proc. Natl. Acad. Sci. USA 88:10500-4
15. Honda R, Ohba Y, Nagata A, Okayama H, Yasuda H. 1993. Dephosphorylation of human p34cdc2 kinase on both Thr-14 and Tyr-15 by human cdc25B phosphatase. FEBS Lett. 318:331-34
16. Lammer C, Wagerer S, Saffrich R, Mertens D, Ansorge W, Hoffmann I. 1998. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J. Cell Sci. 111(Pt. 16):2445-53
17. Baldin V, Cans C, Knibiehler M, Ducommun B. 1997. Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272:32731-34
18. Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. 1996. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell Sci. 109(Pt. 5):1081-93
19. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. 1999. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J. Cell Biol. 146:573-84
20. Sebastian B, Kakizuka A, Hunter T. 1993. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl. Acad. Sci. USA 90:3521-24
21. Gabrielli BG, Clark JM, McCormack AK, Ellem KA. 1997. Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/Cdk2. J. Biol. Chem. 272:28607-14
22. Hoffmann I, Draetta G, Karsenti E. 1994. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13:4302-10
23. Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, et al. 1994. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13:1549-56
24. Blomberg I, Hoffmann I. 1999. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell Biol. 19:6183-94
25. Mailand N, Podtelejnikov AV, Groth A, Mann M, Bartek J, Lukas J. 2002. Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 21:5911-20
26. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. 2002. Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 21:4875-84
27. Chen MS, Hurov J, White LS, Woodford-Thomas T, Piwnica-Worms H. 2001. Absence of apparent phenotype in mice lacking Cdc25C protein phosphatase. Mol. Cell Biol. 21:3853-61
28. Lincoln AJ, Wickramasinghe D, Stein P, Schultz RM, Palko ME, et al. 2002. Cdc25b phosphatase is required for resumption of meiosis during oocyte maturation. Nat. Genet. 30:446-49
29. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J. 2001. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-47
30. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, et al. 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425-29
31. Zhao H, Watkins JL, Piwnica-Worms H. 2002. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. USA 99:14795-800
32. Donzelli M, Draetta GF. 2003. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4:671-77
33. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, et al. 2001. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414:514-21
34. Ducruet AP, Lazo JS. 2003. Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity. J. Biol. Chem. 278:31838-42
35. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. 1993. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 12:53-63
36. Forrest AR, McCormack AK, DeSouza CP, Sinnamon JM, Tonks ID, et al. 1999. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun. 260:510-15
37. Wegener S, Hampe W, Herrmann D, Schaller HC. 2000. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol. 79:810-15
38. Graves PR, Lovly CM, Uy GL, Piwnica-Worms H. 2001. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20:1839-51
39. Nishijima H, Nishitani H, Seki T, Nishimoto T. 1997. A dual-specificity phosphatase Cdc25B is an unstable protein and triggers p34(cdc2)/cyclin B activation in hamster BHK21 cells arrested with hydroxyurea. J. Cell Biol. 138:1105-16
40. Nagata A, Igarashi M, Jinno S, Suto K, Okayama H. 1991. An additional homolog of the fission yeast cdc25+ gene occurs in humans and is highly expressed in some cancer cells. New Biol. 3:959-68
41. Davezac N, Baldin V, Gabrielli B, Forrest A, Theis-Febvre N, et al. 2000. Regulation of CDC25B phosphatases subcellular localization. Oncogene 19:2179-85
42. Galaktionov K, Jessus C, Beach D. 1995. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9:1046-58
43. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. 1999. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274:18659-66
44. Busino L, Chiesa M, Draetta GF, Donzelli M. 2004. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23:2050-56
45. Xia K, Lee RS, Narsimhan RP, Mukhopadhyay NK, Neel BG, Roberts TM. 1999. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol. Cell Biol. 19:4819-24
46. Wang Z, Wang M, Lazo JS, Carr BI. 2002. Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. J. Biol. Chem. 277:19470-75
47. Nemoto K, Vogt A, Oguri T, Lazo JS. 2004. Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells. Prostate 58:95-102
48. Hassepass I, Voit R, Hoffmann I. 2003. Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J. Biol. Chem. 278:29824-29
49. Bartek J, Lukas J. 2001. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr. Opin. Cell Biol. 13:738-47
50. Bulavin DV, Amundson SA, Fornace AJ. 2002. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr. Opin. Genet. Dev. 12:92-97
51. Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, et al. 2002. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 99:1990-95
52. Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, et al. 2001. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411:102-7
53. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, et al. 2003. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426:87-91
54. Jin J, Shirogane T, Xu L, Nalepa G, Qin J, et al. 2003. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25 A protein phosphatase. Genes Dev. 17:3062-74
55. Molinari M. 2000. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33:261-74
56. Lyon MA, Ducruet AP, Wipf P, Lazo JS. 2002. Dual-specificity phosphatases as targets for antineoplastic agents. Nat. Rev. Drug Discov. 1:961-76
57. Chang L, Karin M. 2001. Mammalian MAP kinase signalling cascades. Nature 410:37-40
58. Tonks NK, Neel BG. 2001. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell Biol. 13:182-95
59. Keyse SM. 2000. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 12:186-92
60. Shen Y, Luche R, Wei B, Gordon ML, Diltz CD, Tonks NK. 2001. Activation of the Jnk signaling pathway by a dual-specificity phosphatase, JSP-1. Proc. Natl. Acad. Sci. USA 98:13613-18
61. Charles CH, Abler AS, Lau LF. 1992. cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene 7:187-90
62. Charles CH, Sun H, Lau LF, Tonks NK. 1993. The growth factor-inducible immediate-early gene 3CH134 encodes a protein-tyrosine-phosphatase. Proc. Natl. Acad. Sci. USA 90:5292-96
63. Sun H, Charles CH, Lau LF, Tonks NK. 1993. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75:487-93
64. Keyse SM, Emslie EA. 1992. Oxidative stress and heat shock induce a human gene encoding a protein-tyrosine phosphatase. Nature 359:644-47
65. Farooq A, Zhou MM. 2004. Structure and regulation of MAPK phosphatases. Cell. Signal. 16:769-79
66. Masuda K, Shima H, Katagiri C, Kikuchi K. 2003. Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK specific phosphatase, at Ser-446. J. Biol. Chem. 278:32448-56
67. Brondello JM, Brunei A, Pouyssegur J, McKenzie FR. 1997. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 272:1368-76
68. Dowd S, Sneddon AA, Keyse SM. 1998. Isolation of the human genes encoding the pyst1 and Pyst2 phosphatases: characterisation of Pyst2 as a cytosolic dual-specificity MAP kinase phosphatase and its catalytic activation by both MAP and SAP kinases. J. Cell Sci. 111:3389-99
69. Grumont RJ, Rasko JE, Strasser A, Gerondakis S. 1996. Activation of the mitogen-activated protein kinase pathway induces transcription of the PAC-1 phosphatase gene. Mol. Cell. Biol. 16:2913-21
70. Groom LA, Sneddon AA, Alessi DR, Dowd S, Keyse SM. 1996. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 15:3621-32
71. Bernaudin M, Tang Y, Reilly M, Petit E, Sharp FR. 2002. Brain genomic response following hypoxia and re-oxygenation in the neonatal rat. Identification of genes that might contribute to hypoxia-induced ischemic tolerance. J. Biol. Chem. 277:39728-38
72. Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Stork PJ. 1999. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J. Biol. Chem. 274:12890-97
73. Seta KA, Kim R, Kim HW, Millhorn DE, Beitner-Johnson D. 2001. Hyppxia-induced regulation of MAPK phosphatase-1 as identified by subtractive suppression hybridization and cDNA microarray analysis. J. Biol. Chem. 276:44405-12
74. Brondello JM, Pouyssegur J, McKenzie FR. 1999. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK- dependent phosphorylation. Science 286:2514-17
75. Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, et al. 1998. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 280:1262-65
76. Aref S, Fouda M, El Dosoky E, Menessy A, Mabed M, et al. 2003. c-Myc oncogene and Cdc25A cell activating phosphatase expression in non-Hodgkin's lymphoma. Hematology 8:183-90
77. Loffler H, Syljuasen RG, Bartkova J, Worm J, Lukas J, Bartek J. 2003. Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 22:8063-71
78. Ding XL, Husseman J, Tomashevski A, Nochlin D, Jin LW, Vincent I. 2000. The cell cycle Cdc25 A tyrosine phosphatase is activated in degenerating postmitotic neurons in Alzheimer's disease. Am. J. Pathol. 157:1983-90
79. Vincent I, Bu B, Hudson K, Husseman J, Nochlin D, Jin L. 2001. Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease. Neuroscience 105:639-50
80. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, et al. 1995. CDC25 phosphatases as potential human oncogenes. Science 269:1575-77
81. Yao Y, Slosberg ED, Wang L, Hibshoosh H, Zhang YJ, et al. 1999. Increased susceptibility to carcinogen-induced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 18:5159-66
82. Ma ZQ, Chua SS, DeMayo FJ, Tsai SY. 1999. Induction of mammary gland hyperplasia in transgenic mice overexpressing human Cdc25B. Oncogene 18:4564-76
83. Ma ZQ, Liu Z, Ngan ES, Tsai SY. 2001. Cdc25B functions as a novel coactivator for the steroid receptors. Mol. Cell Biol. 21:8056-67
84. Zou X, Tsutsui T, Ray D, Blomquist JF, Ichijo H, et al. 2001. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol. Cell Biol. 21:4818-28
85. Nishikawa Y, Carr BI, Wang M, Kar S, Finn F, et al. 1995. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 270:28304-10
86. Pumiglia KM, Decker SJ. 1997. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA 94:448-52
87. Liu DX, Greene LA. 2001. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res. 305:217-28
88. McShea A, Wahl AF, Smith MA. 1999. Re-entry into the cell cycle: a mechanism for neurodegeneration in Alzheimer disease. Med. Hypotheses 52:525-27
89. Nagy Z, Esiri MM, Smith AD. 1998. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience 87:731-39
90. Smith MZ, Nagy Z, Esiri MM. 1999. Cell cycle-related protein expression in vascular dementia and Alzheimer's disease. Neurosci. Lett. 211:45-48
91. Kruman II, Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, et al. 2004. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41:549-61
92. Vincent I, Jicha G, Rosado M, Dickson DW. 1997. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci. 17:3588-98
93. Rideout HJ, Wang Q, Park DS, Stefanis L. 2003. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J. Neurosci. 23:1237-45
94. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. 2003. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am. J. Pathol. 162:1807-15
95. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, et al. 1987. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-81
96. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, et al. 1988. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc. Natl. Acad. Sci. USA 85:1571-75
97. Masuda K, Shima H, Kikuchi K, Watanabe Y, Matsuda Y. 2000. Expression and comparative chromosomal mapping of MKP-5 genes DUSP10/Dusp10. Cytogenet. Cell Genet. 90:71-74
98. Schneider BG, Pulitzer DR, Brown RD, Prihoda TJ, Bostwick DG, et al. 1995. Allelic imbalance in gastric cancer: an affected site on chromosome arm 3p. Genes Chromosomes Cancer 13:263-71
99. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, et al. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res. 56:2411-16
100. Yokota J, Tsukada Y, Nakajima T, Gotoh M, Shimosato Y, et al. 1989. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res. 49:3598-601
101. Theodosiou AM, Rodrigues NR, Nesbit MA, Ambrose HJ, Paterson H, et al. 1996. A member of the MAP kinase phosphatase gene family in mouse containing a complex trinucleotide repeat in the coding region. Hum. Mol. Genet. 5:675-84
102. Bepler G, Garcia-Blanco MA. 1994. Three tumor-suppressor regions on chromosome lip identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc. Natl. Acad. Sci. USA 91:5513-17
103. Hoornaert I, Marynen P, Goris J, Sciot R, Baens M. 2003. MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation. Oncogene 22:7728-36
104. Montpetit A, Boily G, Sinnett D. 2002. A detailed transcriptional map of the chromosome 12p12 tumour suppressor locus. Eur. J. Hum. Genet. 10:62-71
105. Martell KJ, Kwak S, Hakes DJ, Dixon JE, Trent JM. 1994. Chromosomal localization of four human VH1-like protein-tyrosine phosphatases. Genomics 22:462-64
106. Weber RG, Rieger J, Naumann U, Lichter P, Weller M. 2001. Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. Int. J. Cancer 91:213-18
107. Ojopi EP, Rogatto SR, Caldeira JR, Barbieri-Neto J, Squire JA. 2001. Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast. Genes Chromosomes Cancer 30:25-31
108. Murty VV, Reuter VE, Bosl GJ, Chaganti RS. 1996. Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors. Oncogene 12:2719-23
109. Peng HQ, Liu L, Goss PE, Bailey D, Hogg D. 1999. Chromosomal deletions occur in restricted regions of 5q in testicular germ cell cancer. Oncogene 18:3277-83
110. Faulkner SW, Friedlander ML. 2000. Molecular genetic analysis of malignant ovarian germ cell tumors. Gynecol. Oncol. 77:283-88
111. Emslie EA, Jones TA, Sheer D, Keyse SM. 1994. The CL100 gene, which encodes a dual specificity (Tyr/Thr) MAP kinase phosphatase, is highly conserved and maps to human chromosome 5q34. Hum. Genet. 93:513-16
112. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. 1996. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 13:925-31
113. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, et al. 1996. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol. Cell Biol. 16:3923-33
114. Magi-Galluzzi C, Mishra R, Fiorentino M, Montironi R, Yao H, et al. 1997. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76:37-51
115. Bang YJ, Kwon JH, Kang SH, Kim JW, Yang YC. 1998. Increased MAPK activity and MKP-1 overexpression in human gastric adenocarcinoma. Biochem. Biophys. Res. Commun. 250:43-47
116. Wang HY, Cheng Z, Malbon CC. 2003. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191:229-37
117. Liao Q, Guo J, Kleeff J, Zimmermann A, Buchler MW, et al. 2003. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 124:1830-45
118. Denkert C, Schmitt WD, Berger S, Reles A, Pest S, et al. 2002. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer 102:507-13
119. Loda M, Capodieci P, Mishra R, Yao H, Corless C, et al. 1996. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149:1553-64
120. Franklin CC, Srikanth S, Kraft AS. 1998. Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc. Natl. Acad. Sci. USA 95:3014-19
121. Liu Y, Gorospe M, Yang C, Holbrook NJ. 1995. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N- terminal kinase activity and AP-1-dependent gene activation. J. Biol. Chem. 270:8377-80
122. Sanchez-Perez I, Martinez-Gomariz M, Williams D, Keyse SM, Perona R. 2000. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19:5142-52
123. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, et al. 2004. Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 23:894-904
124. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. 2003. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537-49
125. Dancey J, Sausville EA. 2003. Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2:296-313
126. Fauman EB, Cogswell JP, Lovejoy B, Rocque WJ, Holmes W, et al. 1998. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 93:617-25
127. Reynolds RA, Yem AW, Wolfe CL, Deibel MR Jr, Chidester CG, Watenpaugh KD. 1999. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J. Mol. Biol. 293:559-68
128. Kristjánsdóttir K, Rudolph J. 2004. Cdc25 phosphatases and cancer. Chem. Biol. 11:1043-51
129. Gunasekera SP, McCarthy PJ, Kelly-Borges M, Lobkovsky E, Clardy J. 1996. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 118:8759-60
130. Ham SW, Park HJ, Lim DH. 1997. Studies on menadione as an inhibitor of the cdc25 phosphatase. Bioorg. Chem. 25:33-36
131. Horiguchi T, Nishi K, Hakoda S, Tanida S, Nagata A, Okayama H. 1994. Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem. Pharmacol. 48:2139-41
132. Loukaci A, Le SI, Samadi M, Leclerc S, Damiens E, et al. 2001. Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorg. Med. Chem. 9:3049-54
133. Wipf P, Hopkins CR, Phillips EO, Lazo JS. 2002. Separation of Cdc25 dual specificity phosphatase inhibition and DNA cleaving activities in a focused library of analogs of the antitumor antibiotic Dnacin. Tetrahedron 58:6367-72
134. Brohm D, Waldmann H. 1998. Stereoselective synthesis of the core structure of the protein phosphatase inhibitor dysidiolide. Tetrahedron Lett. 39:3995-98
135. Brohm D, Metzger S, Bhargava A, Muller O, Lieb F, Waldmann H. 2001. Natural products are biologically validated starting points in structural space for compound library development: Solid-phase synthesis of dysidiolide-derived phosp hatase inhibitors. Angew. Chem.-Int. Ed. 41:307-11
136. Sodeoka M, Sampe R, Kojima S, Baba Y, Usui T, et al. 2001. Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition. J. Med. Chem. 44:3216-22
137. Kar S, Lefterov IM, Wang M, Lazo JS, Scott CN, et al. 2003. Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. Biochemistry 42:10490-97
138. Poigny S, Nouri S, Chiaroni A, Guyot M, Samadi M. 2001. Total synthesis and determination of the absolute configuration of coscinosulfate. A new selective inhibitor of Cdc25 protein phosphatase. J. Org. Chem. 66:7263-69
139. Wipf P, Aslan DC, Luci DK, Southwick EC, Lazo JS. 2000. Synthesis and biological evaluation of a targeted library of protein phosphatase inhibitors. Biotechnol Bioeng. 71:58-70
140. Kitaide M, Nagai K, Terada T, Asao T, Sugimoto Y, Yamada Y. 2001. JP Patent No. 2003104964
141. Peng H, Xie W, Otterness DM, Cogswell JP, McConnell RT, et al. 2001. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. J. Med. Chem. 44:834-48
142. Fritzen EL, Brightwell AS, Erickson LA, Romero DL. 2000. The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity. Bioorg. Med. Chem. Lett. 10:649-52
143. Galcera Contour MO, Lavergne O, Brezak Pannetier MC, Prevost G. 2002. WO Patent No. 2003055868
144. Sohn J, Kiburz B, Li Z, Deng L, Safi A, et al. 2003. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. J. Med. Chem. 46:2580-88
145. Lazo JS, Asian DC, Southwick EC, Cooley KA, Ducruet AP, et al. 2001. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 44:4042-49
146. Lazo JS, Nemoto K, Pestell KE, Cooley K, Southwick EC, et al. 2002. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 61:720-28
147. Wipf P, Aslan DC, Southwick EC, Lazo JS. 2001. Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases. Bioorg. Med. Chem. Lett. 11:313-17
148. Pfahl M, Al shamma HA, Fanjul AN, Pleynet DPM, Bao H, et al. 2002. WO Patent No. 2003050098
149. Brezak MC, Quaranta M, Mondesert O, Galcera MO, Lavergne O, et al. 2004. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer Res. 64:3320-25
150. Taylor NR, Borhani D, Epstein D, Rudolph J, Ritter K, et al. 2001. U.S. Patent No. 2002183249
151. Baurle S, Blume T, Gunther J, Henschel D, Hillig RC, et al. 2004. Design and synthesis of macrocyclic inhibitors of phosphatase Cdc25B. Bioorg. Med. Chem. Lett. 14:1673-77
152. Vogt A, Cooley KA, Brisson M, Tarpley MG, Wipf P, Lazo JS. 2003. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem. Biol. 10:733-42